New study peers into diabetic eyes to see how popular drugs impact vision
NCT ID NCT07536516
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how certain diabetes medications (semaglutide, liraglutide, and tirzepatide) affect blood flow and oxygen use in the eyes of people with diabetes. Researchers will use special cameras to measure eye blood vessels and oxygen levels in 20 adults before and after starting these drugs. The goal is to learn more about how these treatments might influence eye health, especially diabetic retinopathy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonists (semaglutide, liraglutide) and GIP/GLP-1 dual agonist (tirzepatide)
What this could lead to
If successful, this could help doctors understand how common diabetes drugs affect eye health, potentially guiding safer treatment choices.
What could go wrong
This is a small, early observational study with only 20 participants. It measures eye changes but does not test whether the drugs cause harm or benefit directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University Vienna
RECRUITINGVienna, State of Vienna, 1090, Austria